Under the leadership of Commissioner Tukaram Mundhe, the Maharashtra Food and Drug Administration (FDA) has witnessed a massive 300% spike in monthly sample collection. A major crackdown has flagged thousands of sub-standard food and drug samples across the state.

  • Sample collection rates have surged by 300% under Commissioner Tukaram Mundhe.
  • Over 37,000 samples were collected between June and August 2026.
  • Over 15,000 samples failed to meet prescribed quality standards.

The Maharashtra Food and Drug Administration (FDA) has implemented a massive crackdown on food and drug quality, resulting in a staggering 300% increase in monthly sample collection compared to the 2025-26 period. This aggressive surge follows the appointment of Tukaram Mundhe as the FDA Commissioner, who launched a statewide inspection drive shortly after taking charge in May.

Between June and August 2026, the department collected a total of 37,604 samples. This included 34,584 food samples and 3,020 samples related to drugs and cosmetics. Out of the 32,604 samples tested during this three-month window, a significant 15,268 samples were found to be non-compliant with prescribed standards, highlighting a critical issue regarding product safety in the state.

Read Also:Jalna Collector Urges Manoj Jarange Patil to End Hunger Strike Amid Rising Tension

Why This Matters

BozokMedia analysis shows that this exponential rise in testing is not merely a statistical anomaly but a deliberate regulatory shift. By increasing the frequency and volume of testing, the FDA is effectively shrinking the window of opportunity for manufacturers to distribute adulterated or sub-standard goods, thereby protecting public health on a massive scale.

The surge in testing activity is a clear indicator of a shift toward proactive rather than reactive governance in public health safety.

A granular look at the data reveals that food sample collection rose by an average of 340%, while food sample testing skyrocketed by 435%. For the drugs and cosmetics segment, collection increased by 175% and testing by 165%. The crackdown also identified eight spurious drug samples, which poses a severe threat to consumer safety.

Historical Background

Historically, the Maharashtra FDA has faced challenges in maintaining consistent inspection frequencies across all districts. Prior to the current administration, the average monthly collection stood at approximately 3,967 samples. The current regime has nearly tripled this capacity, utilizing a network of six specialized laboratories located in Mumbai, Chhatrapati Sambhajinagar, and Nagpur, alongside the State Public Health Laboratory in Pune.

This systemic overhaul aims to create a more rigorous regulatory environment where substandard products are identified and removed from the supply chain before they reach the mass market.

Did You Know?: Spurious drugs are not just low quality; they are often counterfeit products designed to mimic genuine medicines, posing life-threatening risks.

Frequently Asked Questions

Question 1: How many samples were found to be of sub-standard quality?
Answer: Approximately 15,268 samples failed to meet the prescribed standards during the June-August period.

Question 2: Where are the FDA's main testing laboratories located?
Answer: The primary laboratories are located in Mumbai, Chhatrapati Sambhajinagar, and Nagpur.